Eli Lilly and Company $LLY Shares Acquired by Kathmere Capital Management LLC

Kathmere Capital Management LLC grew its stake in Eli Lilly and Company (NYSE:LLY) by 22.6% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,463 shares of the company’s stock after purchasing an additional 824 shares during the period. Kathmere Capital Management LLC’s holdings in Eli Lilly and Company were worth $4,105,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Maryland Capital Advisors Inc. purchased a new stake in Eli Lilly and Company in the 4th quarter valued at $25,000. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company during the 4th quarter worth $25,000. Vermillion & White Wealth Management Group LLC boosted its position in shares of Eli Lilly and Company by 84.2% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after acquiring an additional 16 shares during the last quarter. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $30,000. Finally, Maseco LLP increased its position in Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. HSBC lowered shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their target price for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Guggenheim reaffirmed a “buy” rating and set a $1,183.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, May 5th. Leerink Partners increased their price objective on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Bank of America raised their target price on Eli Lilly and Company from $1,133.00 to $1,251.00 and gave the stock a “buy” rating in a research note on Tuesday, May 26th. Finally, Cantor Fitzgerald lifted their target price on Eli Lilly and Company from $1,230.00 to $1,350.00 and gave the company an “overweight” rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,243.22.

Eli Lilly and Company Trading Up 3.3%

NYSE:LLY traded up $39.14 during trading hours on Tuesday, reaching $1,239.20. 946,667 shares of the stock were exchanged, compared to its average volume of 3,212,417. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The business has a 50-day moving average of $1,065.45 and a two-hundred day moving average of $1,027.90. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,249.45. The company has a market capitalization of $1.17 trillion, a price-to-earnings ratio of 43.93, a PEG ratio of 1.51 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the previous year, the business earned $3.34 EPS. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 35.74 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: JPMorgan lifted its price target on Eli Lilly to $1,400 and kept an Overweight rating, signaling confidence in further upside. Benzinga
• Positive Sentiment: Recent commentary continues to highlight Lilly’s leadership in GLP-1 obesity and diabetes drugs, which remain the main driver of revenue and investor enthusiasm.
• Positive Sentiment: Media coverage notes Lilly’s strong long-term growth case, with some analysts and market commentary pointing to sustained demand from its key drugs and pipeline expansion. Article
• Neutral Sentiment: Lilly also announced a new R&D collaboration with Abbisko and transferred China commercial rights for Verzenios to Innovent, reflecting ongoing portfolio and regional strategy adjustments. Yahoo Finance
• Negative Sentiment: Some recent coverage pointed to regulatory and drug-pricing policy concerns as a headwind, and the stock also slipped in the prior session, suggesting investors are still balancing optimism with policy risk. Yahoo Finance

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.